The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I clinical trial of LAE102 in China and first subject has been dosed. The phase I clinical trial of LAE 102 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of the therapy. The Group targets to bring this precision therapy to overweight and obesity patients who are in need of novel treatment options for achieving quality weight control.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.21 HKD | +1.76% |
|
-8.11% | -73.82% |
1st Jan change | Capi. | |
---|---|---|
-73.82% | 260M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- 2105 Stock
- News Laekna, Inc.
- Laekna, Inc Doses Subject in Phase I Clinical Trial of LAE102 for the Treatment of Obesity